Detection Of Human Kallikrein 10 In Epithelial Ovarian Cancer Patients' Serum And Its Clinical Significance

Background and Purpose:Epithelial ovarian cancer is the leading cause of cancer death among women genital organs. Location of the ovaries deep in the pelvis, not the typical early symptoms of the disease or no obvious symptoms, making early epithelial ovarian cancer diagnosis rate is not high and the prognosis is poor. A widely used tumor marker CA125, its specificity and the early diagnosis is not ideal, so screening new biomarkers for epithelial ovarian cancer is an essential task. Recent years the domestic and the overseas experts study the expression of hk10 in ovarian cancer. They find that hk10 is significantly high in ovarian cancer patients, and conclude that hk10 may be a marker of ovarian cancer which more significant than CA125. In this paper is to detect the serum human tissue kallikrein 10 (hk10) expression in patients with epithelial ovarian cancer and other groups, and investigate the clinical significance of hk10 in the diagnosis of ovarian cancer.Methods:Enzyme-linked immunoassay (ELISA) method was used to detect the hk10 levels in serum in serous cystadenocarcinoma group (n=50, the number of early ovarian cancer patients is 9, and advanced cancer patients is 41), post-operation ovarian cancer group (n=12), benign ovarian tumor group (n=20), benign gynecological disease (higher CA125 values, n=26), other malignant gynecological cancer group (cervical cancer and endometrial carcinoma, n=18) and healthy controls group (n=36) for statistical analysis.Results:1, The level of serum hk10 in the ovarian cancer group was (15.60±9.23)μg·L-1 and the positive rate was 88.00%, in benign ovarian tumor group they were (6.60±2.65)μg·L-1 and 10.00%; in benign gynecological disease group they were (6.92±2.97)μg·L-1 and 15.38%; in other malignant gynecological cancer group they were (6.11±2.42)μg·L-1 and 11.11%, in healthy control group they were (6.00±2.26)μg·L-1 and 11.11%. The level of serum hk10 and the positive rate in ovarian cancer group were significantly higher than those in other groups, and the difference was statistically significant (P<0.01).2, The level of serum hk10 and the positive rate in stageⅢ/Ⅳovarian cancer group were (18.29±9.74)μg·L-1 and 90.24%, inⅠ/Ⅱovarian cancer group they were (9.87±4.04)μg·L-1 and 77.78%(the positive rate of CA125 was 66.67%). The level of serum hk10 in advanced cancer group was higher than it in early ovarian cancer group, and the difference was statistically significant (P<0.01).3, The level of serum hk10 in post-operation ovarian cancer group (the third day after operation) was (13.83±7.56)μg·L-1 , and in the ovarian cancer group before operation was (14.97±8.54)μg·L-1 . The level of serum hk10 in post-operation ovarian cancer group was lower than before operation. Ovarian cancer group had no significant difference comparing to after operation group (P> 0.05).4, In benign gynecological disease group (higher CA125 values), the level of serum CA125 was (114.61±86.79)U·mL-1; the positive rate of it was 100%; the level and the positive rate of serum hk10 were (6.92'2.97)μg·L-1 and 15.38%. Serum CA125 value was all elevated in this group, but the positive rate of serum hk10 was only 15.38%.Conclusion:The serum hk10 level is significantly increased in epithelial ovarian cancer patients, higher than benign ovarian tumor, benign gynecological disease, other malignant gynecological cancer and healthy women. The serum hk10 level in ovarian cancer patients after operation is lower than it before operation. The level of serum hk10 in advanced cancer is higher than it in early ovarian cancer. In early ovarian cancer, the positive rate of serum hk10 is higher than CA125, which has clinical significance in the early diagnosis of ovarian cancer. In benign gynecological disease patients, serum CA125 levels was all increased, but hk10 was increased only in few of them, suggesting hk10 specificity is higher than CA125. hk10 is expected to become a new marker in ovarian cancer diagnosis.